Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Rob Ten Hoedt Biography and Net Worth

EVP of Medtronic

Rob ten Hoedt is the Executive Vice President and President, Europe, Middle East & Africa (EMEA), and a member of the Company’s Executive Committee (ExCom).

From 2009 to 2015, he was Senior Vice President & President for EMEA and Canada with full responsibility for all sales and distribution of Medtronic products and therapies across those regions.

Rob started his career in Medtronic in 1991 as the Marketing Manager for Western Europe’s Neurological business, based in Brussels, Belgium. In 1994, he went on to lead the start-up of Medtronic’s Gastro-Uro business in Europe, for which he subsequently held global responsibility. In 1999, he was appointed Vice President & General Manager of Vitatron, a wholly-owned subsidiary of Medtronic in The Netherlands, with responsibility for developing and marketing pacing devices. Under his leadership, Vitatron built a strong image and market position in the medical technology world.

In 2006, Rob moved to Medtronic’s EMEA Headquarters in Tolochenaz, Switzerland to lead the CardioVascular business for Europe & Central Asia (ECA) as its Vice President.

With over 25 years of experience in the medical device business, Rob has a wealth of experience in sales, sales management, marketing and general management. Before joining Medtronic, Rob held different positions in a number of medical technology companies including Arjo Hospital Equipment and Polystan Benelux, and also ran his own Distributor Company for a number of years.

Rob is the Chairman of the Board of MedTech Europe, the Association representing the medical technology industry in Europe and holds a Board position in Pixium Vision, a company developing innovative Bionic Vision Restoration Systems (VRS). He holds a degree in Commercial Economics from the HAN University of Applied Sciences and a Masters in Marketing from the NIMA Business School in the Netherlands.

What is Rob Ten Hoedt's net worth?: The estimated net worth of Rob Ten Hoedt is at least $3.55 million as of July 10th, 2023. Mr. Ten Hoedt owns 43,802 shares of Medtronic stock worth more than $3,549,276 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Ten Hoedt may own. Learn More about Rob Ten Hoedt's net worth.
How do I contact Rob Ten Hoedt?: The corporate mailing address for Mr. Ten Hoedt and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Rob Ten Hoedt's contact information.
Has Rob Ten Hoedt been buying or selling shares of Medtronic?: Rob Ten Hoedt has not been actively trading shares of Medtronic during the last quarter. Most recently, Hoedt Rob Ten sold 5,514 shares of the business's stock in a transaction on Monday, July 10th. The shares were sold at an average price of $86.58, for a transaction totalling $477,402.12. Following the completion of the sale, the executive vice president now directly owns 43,802 shares of the company's stock, valued at $3,792,377.16. Learn More on Rob Ten Hoedt's trading history.
Who are Medtronic's active insiders?: Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (Chairman of the Board & CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.
Are insiders buying or selling shares of Medtronic?: During the last year, insiders at the medical technology company sold shares 3 times. They sold a total of 50,662 shares worth more than $4,285,162.92. The most recent insider tranaction occured on June, 7th when CEO Geoffrey Martha sold 19,113 shares worth more than $1,601,096.01. Insiders at Medtronic own 0.2% of the company. Learn More about insider trades at Medtronic.
Information on this page was last updated on 6/7/2024.

Rob Ten Hoedt Insider Trading History at Medtronic

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/10/2023	Sell	5,514	$86.58	$477,402.12	43,802
10/14/2022	Sell	2,404	$81.54	$196,022.16	43,483
9/23/2020	Sell	9,584	$104.34	$999,994.56	43,476
9/9/2020	Sell	9,563	$105.05	$1,004,593.15	53,060
5/28/2019	Sell	9,000	$91.88	$826,920.00	58,785
3/20/2017	Sell	50,757	$81.58	$4,140,756.06	59,392

Rob Ten Hoedt Buying and Selling Activity at Medtronic

Medtronic Company Overview

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Today's Range

Now: $81.03

$79.80

$81.26

50 Day Range

MA: $86.90

$79.99

$92.27

2 Week Range

Now: $81.03

$75.96

$92.68

Volume

10,706,827 shs

Average Volume

6,272,357 shs

Market Capitalization

$103.90 billion

P/E Ratio

24.78

Dividend Yield

3.44%

Beta

0.82

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.